PROJECT

Projects

Summary of Investment Information

Project Number

37324

Company Name

HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY

Date SPI Disclosed

Dec 21, 2017

Country

Jordan

Region

Middle East

Projected Board Date

Jun 9, 2017

Environmental Category

B - Limited

Status

Active

Last Updated Date

Jun 12, 2021

Department

Regional Industry - MAS ME & Africa

Industry

Health, Education and Life Sciences

Previous Events

Approved : Jun 23, 2017
Signed : Dec 21, 2017
Invested : Apr 28, 2020

Sector

Pharmaceuticals and Medicine

Project Description

Hikma Pharmaceuticals PLC (“Hikma” or the “Company”) and its subsidiaries (the “Group”), is a generic pharmaceutical company incorporated in United Kingdom(“UK”)and listed on the London Stock Exchange (“LSE”). While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (“MENA”) region, the United States (“US”) and Europe. The Company has 29 manufacturing facilities in 11 countries out of which facilities in 5 countries have received US Food and Drug Administration (“FDA”) approval. Hikma’s main business lines include branded, injectables and generic pharmaceuticals. Hikma is a long-standing IFC client since 1987.

The Company has invited IFC to provide and arrange financing to support the general corporate purposes of the Company and members of its Group in the MENA region and/or in other World Bank Group countries of operation.

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation